StreetInsider.com News Articles

Artelo Biosciences presents drug metabolism data for ART26.12 candidate

Wed, 10 Jun 2026 07:47:26 -0400

Artelo Biosciences Inc. (NASDAQ: ARTL) announced that its lead medicinal chemist presented metabolite data for drug candidate ART26.12 at a pharmaceutical conference in London on June 10.

The data comes from plasma samples of healthy volunteers who participated in a single ascending dose clinical study of ART26.12, the company's FABP inhibitor candidate being developed as a non-opioid pain treatment.

According to the company's findings, only three metabolites were detected in plasma samples from volunteers who received a single 900 mg oral dose of ART26.12. Total metabolite exposure represented approximately 7% of overall drug-related exposure, with the parent compound ART26.12 accounting for the

Artelo Biosciences presents drug metabolism data for ART26.12 candidate

Wed, 10 Jun 2026 07:47:26 -0400

Artelo Biosciences Inc. (NASDAQ: ARTL) announced that its lead medicinal chemist presented metabolite data for drug candidate ART26.12 at a pharmaceutical conference in London on June 10.

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Wed, 10 Jun 2026 07:38:00 -0400

SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicinal Chemist at Artelo, is delivering an oral presentation today highlighting encouraging metabolite identification and profiling data from the Company's lead FABP inhibitor candidate, ART26.12, during the 7th RSC-BMCS/DMDG New Perspectives in DMPK and Medicinal Chemistry Conference, held at the Burlington House in London.

The presentation features results from metabolite

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Wed, 10 Jun 2026 07:38:00 -0400

The presentation features results from metabolite

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Wed, 10 Jun 2026 07:38:00 -0400

The presentation features results from metabolite

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Wed, 10 Jun 2026 07:38:00 -0400

The presentation features results from metabolite

Form ARS ARTELO BIOSCIENCES, INC. For: Dec 31

Fri, 05 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260605/26611075.html

Form ARS ARTELO BIOSCIENCES, INC. For: Dec 31

Fri, 05 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260605/26611075.html

Form DEFA14A ARTELO BIOSCIENCES, INC.

Fri, 05 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260605/26611047.html

Form DEFA14A ARTELO BIOSCIENCES, INC.

Fri, 05 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260605/26611047.html

Form DEF 14A ARTELO BIOSCIENCES, INC. For: Jul 17

Fri, 05 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260605/26611002.html

Form DEF 14A ARTELO BIOSCIENCES, INC. For: Jul 17

Fri, 05 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260605/26611002.html

Form 8-K ARTELO BIOSCIENCES, INC. For: May 26

Wed, 27 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260527/26558639.html

Form 8-K ARTELO BIOSCIENCES, INC. For: May 26

Wed, 27 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260527/26558639.html

Form PRE 14A ARTELO BIOSCIENCES, INC. For: Jul 17

Tue, 26 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260526/26551127.html

Form PRE 14A ARTELO BIOSCIENCES, INC. For: Jul 17

Tue, 26 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260526/26551127.html

Artelo Biosciences files $6.5M at-the-market offering prospectus

Tue, 26 May 2026 16:50:02 -0400

Artelo Biosciences (NASDAQ: ARTL) filed a prospectus supplement for an at-the-market offering program to sell up to $6.53 million of common stock through H.C. Wainwright & Co. as exclusive sales agent.

The biotechnology company entered into an At the Market Offering Agreement with H.C. Wainwright dated May 26, 2026. Under the arrangement, shares will be sold at market prices through existing trading markets when and if the company chooses to make sales.

H.C. Wainwright will receive a 3% commission on the gross sales price of shares sold and is not required to sell any specific number or dollar amount of securities. The

Artelo Biosciences files $6.5M at-the-market offering prospectus

Tue, 26 May 2026 16:50:02 -0400

H.C. Wainwright will receive a 3% commission on the gross sales price of shares sold and is not required to sell any specific number or dollar amount of securities. The

Form 424B5 ARTELO BIOSCIENCES, INC.

Tue, 26 May 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260526/26550862.html

Form 424B5 ARTELO BIOSCIENCES, INC.

Tue, 26 May 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260526/26550862.html

Form EFFECT ARTELO BIOSCIENCES, INC.

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524292.html

Form EFFECT ARTELO BIOSCIENCES, INC.

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524292.html

Form 424B5 ARTELO BIOSCIENCES, INC.

Mon, 18 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260518/26514422.html

Form 424B5 ARTELO BIOSCIENCES, INC.

Mon, 18 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260518/26514422.html

Artelo Biosciences terminates at-the-market offering agreement

Fri, 15 May 2026 16:03:22 -0400

Artelo Biosciences Inc. (NASDAQ: ARTL) terminated its at-the-market offering agreement with R.F. Lafferty & Co., Inc., the company announced. The termination notice was provided on May 11, 2026, with the agreement ending on May 18, 2026.

The sales agreement, originally dated July 18, 2025, allowed Artelo to sell up to $6,500,000 worth of common stock through R.F. Lafferty in an at-the-market equity offering program. Under the arrangement, the company could offer and sell shares of its common stock with a par value of $0.001 per share at various times.

Through May 11, 2026, Artelo sold 50,858 shares of common stock under the